Please note: We will be conducting our annual physical inventory counts on September 28 & 29.
Processing times will not be affected but shipping times may be delayed due to this. Thank you for your attention to this and we look forward to continuing
to serve you.
COVID-19 Assay Development Services & Rapid Diagnostic Test Reagents
In light of the continued impact from SARS-CoV-2, the virus responsible for COVID-19, we have seen an increasing demand for assay development services as well as essential reagents. Rapid diagnostic tests are critical tools for screening at-risk populations and managing the spread of the outbreak, and we are actively helping in this fight.
nanoComposix has extensive experience in the LFA serological space, and has worked with both private corporations and government agencies (e.g. CDC, NIAID, NIH, etc.) to develop lateral flow diagnostics for infectious diseases, such as: cytomegalovirus infection, hepatitis C, hepatitis E, Lyme disease, paragonimiasis, loa loa filariasis, and tuberculosis. We are now completing the development of a serological assay for COVID-19 that measures both the IgM and IgG response in whole blood. nanoComposix has the rights to earmark certain tests for white label distribution. Contact us to learn more.
Development of sensitive lateral flow assays requires high performance, robust gold particles, and our BioReady gold reagents are a key component for maximizing the sensitivity and reliability of visual detection point of care tests.
The Nanoshell Advantage
Gold nanoshells can dramatically increase the sensitivity of lateral flow assays as each particle is 30× more strongly colored than 40 nm gold. The dramatic increase in color means that fewer binding events are required in order to see a result at the test line in a lateral flow assay. Learn more about the nanoshell advantage.